GlaxoSmithKline: Papillomavirus Infections trials

The registry lists 72 Papillomavirus Infections studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 48 have results posted.

Phase 1 3Phase 2 11Phase 3 41Phase 4 3No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years OldCompletedNCT01627561Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old FemalesCompletedNCT01462357Phase 3Results posted
• Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 StudyCompletedNCT01418937Phase 3Results posted
• Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old GirlsCompletedNCT01381575Phase 3Results posted
• Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)CompletedNCT01277042Phase 3Results posted
• The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 StudyCompletedNCT01249365Phase 3Results posted
• Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 StudyCompletedNCT01190189Phase 3Results posted
• Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study SubjectsCompletedNCT01190176Phase 3Results posted
• Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean FemalesCompletedNCT01101542Results posted
• Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected FemalesCompletedNCT01031069Phase 4Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female SubjectsCompletedNCT00996125Phase 3Results posted
• Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female SubjectsCompletedNCT00947115Phase 3Results posted
• Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study SubjectsCompletedNCT00937950Phase 3Results posted
• Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 StudyCompletedNCT00929526Phase 3Results posted
• Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.CompletedNCT00877877Phase 3Results posted
• Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or ThailandCompletedNCT00849381Phase 3Results posted
• Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.CompletedNCT00811798Phase 3Results posted
• Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the USCompletedNCT00799825Phase 3Results posted
• Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female SubjectsCompletedNCT00779766Phase 3Results posted
• A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.TerminatedNCT00730847Phase 4Results posted
• Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female SubjectsCompletedNCT00652938Phase 3Results posted
• Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)CompletedNCT00637195Phase 3Results posted
• Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected FemalesCompletedNCT00586339Phase 2Results posted
• Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female SubjectsCompletedNCT00578227Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of AgeCompletedNCT00552279Phase 3Results posted
• A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese FemalesCompletedNCT00549900Phase 1Results posted
• Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North AmericaCompletedNCT00546078Phase 2Results posted
• Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 YrsCompletedNCT00541970Phase 1Results posted
• Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy AdolescentsCompletedNCT00534638Phase 4Results posted
• Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in BrazilCompletedNCT00518336Phase 2Results posted
• Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of AgeCompletedNCT00492544Phase 3Results posted
• A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 YearsCompletedNCT00485732Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.CompletedNCT00481767Phase 3Results posted
• Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 YearsCompletedNCT00456807Phase 3Results posted
• Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female SubjectsCompletedNCT00426361Phase 3Results posted
• Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeCompletedNCT00423046Phase 3Results posted
• Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female SubjectsCompletedNCT00369824Phase 3Results posted
• Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV VaccineCompletedNCT00359619Phase 2Results posted
• Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsCompletedNCT00345878Phase 3Results posted
• Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian WomenCompletedNCT00344032Phase 3Results posted
• Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 VaccineCompletedNCT00316706Phase 3Results posted
• Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 VaccineCompletedNCT00316693Phase 2Results posted
• Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.CompletedNCT00309166Phase 2Results posted
• Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and OlderCompletedNCT00294047Phase 3Results posted
• Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.CompletedNCT00250276Phase 3Results posted
• Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.CompletedNCT00231413Phase 2Results posted
• Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18CompletedNCT00196937Phase 3Results posted
• Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18CompletedNCT00122681Phase 3Results posted
• Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary StudyWithdrawnNCT02100618Phase 3
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 YearsWithdrawnNCT02082639Phase 3
• Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United KingdomCompletedNCT01953822
• Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UKCompletedNCT01905462
• Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) VaccineCompletedNCT01702337
• Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri LankaWithdrawnNCT01551537
• Cervarix Long-term Safety SurveillanceCompletedNCT01498627
• Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in CanadaTerminatedNCT01290393
• Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi ArabiaCompletedNCT01213459
• Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical CancerCompletedNCT01207999
• An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of BahrainCompletedNCT01205412
• Drug Use Investigation for Cervarix®CompletedNCT01187927
• An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in EgyptCompletedNCT01158209
• Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® VaccinationCompletedNCT01153906
• Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in NorwayTerminatedNCT00924794
• Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult FemalesCompletedNCT00693966Phase 2
• Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult FemalesCompletedNCT00693615Phase 2
• Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy WomenCompletedNCT00689741Phase 2
• Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)CompletedNCT00478621Phase 1
• A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsCompletedNCT00306241Phase 3
• Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 YearsCompletedNCT00290277Phase 3
• Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.CompletedNCT00196924Phase 3
• Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18CompletedNCT00169494Phase 3
• Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young AdultsCompletedNCT00120848Phase 2